All Stories

  1. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance

    Article • Risk Management and Healthcare Policy, August 2018, Dove Medical Press

    Dr Alyssa Peckham, Maria Ananickal

  2. VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications

    Article • Journal of Pharmacy Practice, February 2018, SAGE Publications

    Dr Alyssa Peckham

  3. Prevalence of depression and receipt of antidepressant pharmacotherapy among patients with Parkinson’s disease: a national assessment of US office-based physician visits

    Article • Journal of Parkinsonism and Restless Legs Syndrome, November 2017, Dove Medical Press

    Dr Alyssa Peckham

  4. A Survey of Prescribersʼ Attitudes, Knowledge, Comfort, and Fear of Consequences Related to an Opioid Overdose Education and Naloxone Distribution Program

    Article • Journal of Public Health Management and Practice, October 2017, Wolters Kluwer Health

    Dr Alyssa Peckham

  5. All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

    Article • Drug Safety, September 2017, Springer Science + Business Media

    Dr Alyssa Peckham

  6. Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population

    Article • Clinical Drug Investigation, April 2017, Springer Science + Business Media

    Dr Alyssa Peckham

  7. Diagnosis and Treatment of ADHD in the United States: Update by Gender and Race

    Article • Journal of Attention Disorders, February 2017, SAGE Publications

    Dr Alyssa Peckham

  8. Naloxone access laws and implementation of overdose prevention programs at veteran affairs hospitals

    Article • Drug and Alcohol Dependence, February 2017, Elsevier

    Dr Alyssa Peckham